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has been shown to be an active agent in the resolution of experimentally induced inflammation. This
study was undertaken to determine the presence of PGD
2
in chronic joint effusions and to explore the potential contributions
of dendritic cells (DC) and monocytes to the intra-articular synthesis of PGD
2
. Synovial fluid (SF) was obtained from patients




were detected in SF by ultrahigh-performance tandem mass
spectrometry. Cellular fractions in SF were separated by density-gradient centrifugation and flow cytometry. The expression of




were detected in blood and SF, with PGD
2
beingmore abundant than PGE
2
in SF. mRNA for hPGDS was more abundant
in SF mDCs than SF monocytes (𝑃 < 0.01) or PB monocytes (𝑃 < 0.001). SF mDC expressed significantly more hPGDS than
PGES. Expressions of PGD
2
and hPGDS were inversely associated with serum C-reactive protein (𝑃 < 0.01) and erythrocyte
sedimentation rate (𝑃 < 0.01). The findings suggest that synovial DCs may be an important source of hPGDS and that systemic
disease activity may be influenced by actions of PGD
2
in RA and other arthropathies.
1. Introduction









via their respective synthases [1]. Synthesis of
PGE
2
is involved in inflammation, and mice deficient in PGE
synthase had decreased pain responses, decreased delayed-
type hypersensitivity, and suppression of collagen-induced
arthritis [2]. Upstream suppression of PGE synthesis by
inhibitors of COX-2 is thought to explain the analgesic
effects of nonsteroidal anti-inflammatory drugs (NSAIDs),
including the COX-2 inhibitors, on arthritis [3].





in resolving inflammation [4]. NSAIDs inhibit synthesis of
PGD
2
and have been shown to delay resolution of experimen-
tally induced inflammation through a mechanism that can
be overridden by local administration of exogenous PGD
2
[4, 5]. There are two PGD synthase isozymes. Lipocalin-type
PGD synthase is primarily expressed in brain, heart, and
adipose tissue, and hematopoietic PGD synthase (hPGDS) is
mainly expressed in mast cells, macrophages, dendritic cells
(DC), and Th
2
lymphocytes [6]. hPGDS appears to be the
PGD synthase most involved in resolution of inflammation,
since animals that are genetically deficient in hPGDS show
impaired resolution of inflammation, and animals transgenic
for hPGDS have reduced inflammatory responses [7]. The
biological actions for PGD
2





(CRTH2) (for reviews, see
[8, 9]).
We have recently shown that dietary fortification with
vitamin D
3
reduced the severity and duration of adoptively
transferred polyarthritis in rats and that the effect was
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associated with reduced expression of PGE synthase and
increased expression of hPGDS by DCs from synovium-rich
hind paw tissue [10].
PGE
2
has been found in rheumatoid synovial fluid (SF)
[11, 12] with emphasis on its role in inflammation and the
effects of NSAIDs. While the potentially anti-inflammatory
PGD
2
and its nonenzymatic metabolite 15-deoxy PGJ
2
have
been found in synovial fluid, this prostaglandin has received
much less attention [13, 14]. We have examined chronic joint
effusions for the presence of PGD
2
and have explored the
potential contributions of myeloid DC (mDC) and mono-
cytes to the intra-articular synthesis of PGD
2
.
2. Materials and Methods
2.1. Subjects. SF and blood samples were obtained from
patients undergoing arthrocentesis of chronic inflammatory
knee effusions. All patients were ambulatory community
dwellers, and, with the exception of two patients, the remain-
der were known to be vitamin D replete based on serum
25-hydroxy-cholecalciferol being ≥74 nmol/L, or based on
history of regular vitamin D supplementation. While the
vitamin D status in the other two patients was not known,
both were active in outdoor pursuits. Diagnostic details and
medications taken are shown in Table 1. All patients and
healthy donors gave informed consent and the study protocol
was approved by the Human Research Ethics Committee,
Royal Adelaide Hospital Australia.
2.2. Measurement of Systemic Disease Activity. Systemic dis-
ease activity was assessed by routine laboratory testing for










by ultrahigh-performance liquid chromatography tandem
mass spectrometry (UPLC-MS/MS) was undertaken based
on the protocol reported by Unterwurzacher et al. [15].




with quantification using homologous deuterated internal
standards. Unfractionated SF and whole blood samples were
applied to purpose-designed filter papers and stored at
−70∘C until further use. Analysis of 6mm punched filter
paper spots was extracted with 100 𝜇L of acetonitrile : water
mixture containing the stable isotopes. A volume of 10 𝜇L
was injected onto a reversed phase column (ZORBAXEclipse
XDB C18, 3.0× 100mm, 3.5 𝜇m particle size, Agilent Tech-
nologies, Vienna, Austria).The prostanoids were eluted using
a gradient of water to 100% acetonitrile/0.05% formic acid
into a AB Sciex API 5000 QJet triple quadrupole instrument.
The concentration of each analyte was determined against









-d4) from Cayman Europe
Chemicals.
2.4. Isolation of Mononuclear Cells from SF and Peripheral
Blood (PB). SF and blood samples were collected into hep-
arinised tubes. SF was diluted in RPMI containing 2% fetal
bovine serum (complete medium) prior to centrifugation for
10 minutes at 293 g [16]. The SF cells were resuspended in
completemedium. Resuspended SF cells and blood cells were
fractionated by centrifugation on a Lymphoprep density gra-
dient at 600 g for 30 minutes in order to isolate mononuclear
cells. All cell analyses were undertaken on freshly isolated
cells.
2.5. Flow Cytometric Analysis. Flow cytometric analysis was
performed as described previously [10]. The following anti-
bodies were used: Alexa fluor 488 anti-human CD11b,
HLADR PE-cy5, PE-CD11c, PE-CD163, PE-CD14, and APC-
CD14 (BD Biosciences, San Jose, CA, USA). Relevant isotype
controls were used throughout. Labelled cells were analysed
with a Beckman Coulter EPICS XL-MCL flow cytometer and
Coulter EXPO 32 software (Beckman Coulter, Fullerton, CA,
USA).
2.6. Isolation of Myeloid DCs and Monocytes by Flow Cytome-
try. SF mononuclear cells separated by gradient density were
labelledwith a cocktail of conjugatedmAbs comprisingAlexa
fluor 488-CD11b, phycoerythrin CD11c, PE-cy5 HLADR, and
APC-CD14 for 45min at 4∘C as described previously [10].
Cells were gated by size (Figure 2(a)) and subsequently
sorted into CD11b+ HLADR+ CD11c+ CD14− (mDC) and
CD11b+ HLADR+ CD11c+ CD14+ (monocytes) (Figure 2(e))
populations, using FACS Diva software (Becton Dickinson),
as described previously [17]. PB blood mononuclear cells
were labelled with PE anti-CD14mAb followed by separation
of CD14+ cells by cell sorter.
2.7. Cytology. Cytospin smears prepared from flow cytomet-
rically sorted cells were fixed and stained as described [18].
2.8. RNA Isolation and Quantitative RT-PCR Analysis of Gene
Expression. Total RNA was extracted from flow cytomet-
rically sorted cell populations using the RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) according to themanufacturer’s
instructions. Total RNA was reverse-transcribed to cDNA
and amplified using the two-step reverse transcription-
polymerase chain reaction (RT-PCR) kit from Qiagen. RNA
and cDNA quality was assessed using a NanoDrop 1000
spectrophotometer (ThermomFisher Scientific, Wil ington,
DE, USA) before samples were frozen at −70∘C until further
use. Gene expression levels were investigated using commer-
cially available specific primers for human genes obtained






Real-time PCR was performed using the QuantiFast SYBR
Green PCR kit (Qiagen) according to the supplier’s protocol,
in a Rotor-Gene 3000 real-time PCR machine (Corbett
Research, NSW, Australia). A minimum of three replicates of
each sample was amplified in all experiments. Each PCR had
a sample prepared without template and a sample prepared
without primers, serving as negative controls. The reactions
were incubated at 95∘C for 5min followed by 35 cycles of
95∘C for 10 s and 60∘C for 30 s. PCR product quality was
monitored using post-PCRmelt curve analysis. Fold changes
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Table 1: Demographic and clinical characteristics of patients.
Diagnosis Age (years) Sex (years) Disease duration Treatment
RA 83 F 18 DMARDs + NSAIDs + vitD + fish oil
RA 53 F 3 DMARDs + NSAIDs + fish oil
RA 82 F 30 DMARDs + vitD + fish oil
RA 48 F 22 DMARDs + NSAIDs + fish oil
RA 61 F 13 Tocilizumab + fish oil
RA 57 F 27 DMARDs + Adalimumab + fish oil
RA 60 F 38 DMARDs + vitD + fish oil
RA 62 F 2 NSAIDs
RA 82 F 11 DMARDs + fish oil
RA 50 F 1 DMARDs + vitD + fish oil
RA 66 F 10 DMARDs + vitD
RA 67 F 29 DMARDs + vitD
RNP+ polyarthritis 55 F 3 DMARDs + NSAIDs + vitD + fish oil
B27+ Pauci-arthritis 35 F 18 DMARDs + vitD + fish oil
Psoriatic arthritis 58 F 6 DMARDs + vitD + fish oil
Psoriatic arthritis 55 F 2 Fish oil
B27+ spondyloarthritis 62 M 41 DMARDs + NSAIDs + fish oil
Juvenile onset-monoarthritis 34 F 26 NSAIDs
Crohn’s arthritis 46 F 30 DMARDs + vitD
Crohn’s arthritis 70 F 13 DMARDs + NSAIDs + vitD + fish oil
RA: rheumatoid arthritis; DMARDs: disease-modifying anti-inflammatory drugs; NSAIDs: nonsteroidal anti-inflammatory drugs.
were calculated using the formula 2−(ΔCt), where ΔCt = Ct
(target gene) − Ct (𝛽-actin) [19].
2.9. Statistical Analysis. All data were analyzed using Graph-
Pad Prism V5.0 (GraphPad Software, Inc., San Diego, CA,
USA). Quantitative real-time RT-PCR signals were normal-
ized to 𝛽-actin. One-way analysis of variance (ANOVA)
with Newman-Keuls post hoc test was used to determine
significant differences between groups. C-reactive protein
(CRP) and ESR correlation to hPGDS expression by SF







in Inflammatory Synovial Fluid. There





blood (Figure 1) whereas the concentration of PGD
2
was
substantially greater than that of PGE
2
in knee effusions
from patients with inflammatory arthropathies (𝑃 < 0.01)
(Figure 1).
3.2. Expression of hPGD and PGE Synthases by Myeloid
Dendritic Cells (mDCs) and Monocytes Isolated from Syn-
ovial Fluid. Populations of mononuclear cells in SF were
characterised by three- and four-colour flow cytometry.
The forward light scatter gate was chosen (Figure 2(a)) to
exclude most lymphocytes and neutrophils and to include
monocytes, macrophages, and DCs. CD11b antibody, which
detectsmyeloid haematopoietic cells, stained about half of the
cells in this gate. The CD11b stained cells comprised a single
∗ ns















in synovial fluid and
whole blood. Lines connect results from the sameperson. ∗𝑃 < 0.01;
ns: not significant.
peak of fluorescence,whichwaswell resolved fromunlabelled
cells (Figure 2(b)). About 80% of the CD11b+ HLADR+ cells
in SF expressed CD11c (Figure 2(c)), consistent with their
designation as monocytes or mDC.The minority population
(20%) of CD11b+HLADR+ cells appeared to bemacrophages
as evinced by proportionate staining for the macrophage
marker CD163+ (Figure 2(d)). Based on CD14 staining in
four-colour flow cytometric (Figure 2(e)) and cytospin anal-
yses (Figures 2(f) and 2(g)), the CD11b+ HLADR+ CD11c+
cells were separated into mDC (5%) (CD14−, Figure 2(e);
























Figure 2: Flow cytometric analysis of cells prepared from SF aspirates. (a) Shows the selected gate based on forward and side scatter of light.
(b) ShowsCD11b staining of 50% of SF cells in a single peak. (c) Shows 3-colour flow cytometric analysis in which 80% of CD11b+HLADR+ SF
cells express CD11c. (d) Shows 3-colour analysis of SF cells in which 20% of CD11b+HLADR+ cells express CD163. (e) Shows 4-colour analysis
to separate CD14− from CD14+ subsets of HLADR+ CD11b+ CD11c+ cells. The CD14− cells were enriched for cells with DCmorphology (f),
whereas the CD14+ subpopulation displayed monocyte morphology (g).
DC morphology, Figure 2(f)) and monocytes (75%) (CD14+,
Figure 2(e); monocyte morphology, Figure 2(g)).
The expression of mRNA for hPGDS by SF mDC was
greater in SF mDC than in SF monocytes (𝑃 < 0.0001)
or peripheral blood monocytes (𝑃 < 0.0001) (Figure 3(a)).
mRNA for the PGD receptor DP
2
was increased in SF
mDC and peripheral blood monocytes compared with SF





(data not shown) or the poten-
tially competing terminal synthase PGES (Figure 3(c)) was
detected in SFmDCandmonocytes. As shown in Figure 3(d),




Expression and Disease Activity. The higher level
of PGD
2
in synovial fluid and higher expression of hPGDS
by SF mDC seen in some patients was intriguing and
led us to explore a possible correlation with inflammatory
disease activity (Figure 4). CRP and ESR levels were inversely
correlated with synovial fluid concentration of PGD
2
and
synovial fluid mDC expression of hPGDS (Figure 4).
Mediators of Inflammation 5































































Figure 3: Expression of mRNA for (a) hPGDS, (b) PGD receptor DP
2
, (c) PGES in SF myeloid DC, SF monocytes, and PB monocytes, and
(d) hPGDS versus PGES in SF mDC in patients with inflammatory arthritis. ∗𝑃 < 0.01, ∗∗𝑃 < 0.0001, ns: not significant.
4. Discussion
Theprogression fromacute to chronic inflammation has been
viewed as a persistence of excess proinflammatorymediators,
but more recent studies show that it may also arise from
a failure of mechanisms that resolve inflammation [20].
Although mononuclear cells can in many settings contribute
to proinflammatory responses, they are also critical in tissue
repair in a noninflammatory manner [21]. Most successful
inflammatory processes are self-limiting, which implies the
existence of endogenous anti-inflammation pathways [22].
A number of mediators, including PGD
2
, have been
shown to actively promote resolution of inflammation [22,
23]. PGDS knockout mice had impaired resolution of inflam-
mation whereas PGDS transgenic mice had reduced inflam-
matory responses [7]. PGD
2
suppresses joint inflammation in
murine collagen-induced arthritis [24]. We have shown that
dietary fortificationwith vitaminD3 reduced the severity and
duration of adoptively transferred polyarthritis (ATA) in rats,
and this was associated with increased expression of hPGDS
and reduced expression of PGES by mDC from synovium-
rich hind paw tissue of arthritic rats [10]. The source of SF
PGD
2
probably involves cells other than SFmDCs. Mast cells
contain PGDS and anti-IgE stimulates PGD
2
synthesis in
human and rat mast cells [25]. However, antigen presenting
cells including DC were the major source of hPGDS in
various rat tissues even though there was expression in mast
cells [26]. In human skin, all of the antigen presenting cells
express hPGDS, and this includes Langerhans cells, dermal
DCs, and plasmacytoid and myelocytic DCs. The authors
reporting these observations acknowledge that mast cells
produce PGD
2
but conclude that epidermal DCs such as
Langerhans cells should be a major source of PGD
2
in skin at
least [27].While there appear to be no prior reports linking SF
mDCs to production of PGD
2
, monocyte-derived DCs have
been shown to produce PGD
2
[27].
In the present study, we observed that SF from patients
with inflammatory arthritis contains significantly greater
6 Mediators of Inflammation






















































































































Figure 4: Pearson’s correlations between systemic disease activity measured by CRP or ESR and (a) synovial concentrations of PGD
2
, and







. SF mDCs were found to express
significantly more hPGDS than PGES. PGD
2
may affect
various immune cells and effector cells, including mDCs
themselves through the DP
2
receptor, which we found is
more strongly expressed in SFmDCs and PBmonocytes than







) has the ability to
modulate the function and maturation of monocyte-derived
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DC [28, 29]. While 15d-PGJ
2
can interact with the DP
2
receptor, there is longstanding controversy as to whether it is
an endogenous mediator, especially of PPAR𝛾, due to its very
low levels in vivo [30]. Factors which enhance the expression
of PGD synthase should have useful anti-inflammatory effect.
The participants in this study were replete in vitamin D
which we have shown to upregulate joint mDC hPGDS in rat
polyarthritis [10].
There were no significant differences in the expression of
PGES between SF mDCs or SF or peripheral blood mono-
cytes. Both SF mDCs and monocytes expressed little COX2
constitutively, although we have observed that COX2 expres-
sion is significantly upregulated by these cells in response
to LPS stimulation (data not shown). As mentioned above,
SF mDCs expressed significantly lower level of PGES than
PGDS. It is possible that the anti-inflammatory treatments
applied may have influenced PGES expression [31, 32]. Our
practice is to advise patients to avoid NSAIDs in favour of an
anti-inflammatory dose of fish oil and to use NSAIDs sparing
as needed for 2nd-line analgesia on grounds of safety and the
lack of a favourable disease modifying effect with NSAIDs
use. Onmechanistic grounds, onemight expect regular, more
intensive NSAIDs use to yield symptomatic benefit from
reduced PGE
2
synthesis achieved through the reduction of
the precursor COX-2 product PGH
2
, which is the substrate
for both PGES and PGDS. However, a concomitant reduction
in PGD
2
synthesis would be expected to compromise disease
control and resolution. While conventional and biological
disease modifying antirheumatic drugs (DMARDs) may
conceivably influence the production of PG, the effects
are likely indirect. The issue has been most thoroughly
investigated with methotrexate with conflicting findings
[33–35].








involved in resolution of inflammation, acting on cell traffic
and cytokine synthesis in animal models [5, 7, 36]. Colonic
mucosal synthesis of PGD
2
, which is specifically upregulated
during remission from ulcerative colitis, may contribute to
the maintenance of remission in these patients [37]. The
finding of hPGDS in human synovial mDC as well as
PGD
2
in synovial fluid and the inverse relation to disease
activity prompts the question of whether mediators present
in inflamed joints are inducers of hPGDS in human SF DCs.
If so, suppression of the synthesis or action of thesemediators
by NSAIDs may suppress the development of the natural
resolution phase of inflammation.
In conclusion, the findings indicate that synovial mDCs
exhibit expression characteristics appropriate for an active
role in PGD
2
synthesis and that PGD
2
is present in inflam-
matory effusions. The inverse correlation of both PGD
2
and
expression of hPGDS in mDCs in SF with the markers of
systemic disease activity (CRP and ESR) suggests that sys-
temic disease activity may be influenced by actions of PGD
2
in rheumatoid arthritis and other arthropathies. Within this
small sample of patients, most of whom had rheumatoid
arthritis, this putative effect was not obviously influenced by
the type of arthropathy or DMARD therapy. It remains to be
determined if the elevated PGDS in SFmDCs andPGD
2
in SF
observed in patients who had low CRP and ESR contributes
to remission in RA group of patients.
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